Biomarkers for the identification of recurrence in human epidermal growth factor receptor 2-positive breast cancer patients.
Pruneri, Giancarlo; Bonizzi, Giuseppina; Vingiani, Andrea.
Curr Opin Oncol
; 28(6): 476-483, 2016 11.
Artigo em Inglês | MEDLINE | ID: mdl-27649027
Trastuzumab-containing regimens for metastatic breast cancer.
Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials.
Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer.
The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer--a systematic review.
High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials.
Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.
Dual HER2 blockade: preclinical and clinical data.